RHB-105: Phase III amended

RedHill amended the double-blind, placebo-controlled, U.S. Phase III ERADICATE Hp trial of oral RHB-105 to increase enrollment to 120 patients from 90. The company said the changes improve the study's statistical powering and reduce the potential effect of non-compliant patients. ERADICATE Hp is evaluating RHB-105 thrice daily for 14 days in patients with confirmed H. pylori infection and non-investigated dyspepsia. ...